Ignite Creation Date:
2024-05-19 @ 5:35 PM
Last Modification Date:
2024-10-26 @ 3:29 PM
Study NCT ID:
NCT06414733
Status:
NOT_YET_RECRUITING
Last Update Posted:
2024-06-06
First Post:
2024-05-10
Brief Title:
Vaccine Therapy in Treating Patients With Metastatic Solid Tumors
Sponsor:
Pravin TP Kaumaya
Organization:
Indiana University
Study Overview
Official Title:
Phase Ib Active Immunotherapy Trial Expansion With a Combination of Two Chimeric Trastuzumab-like and Pertuzumab-like HER-2 B Cell Peptide Vaccine Emulsified in ISA 720 Adjuvant in Patients With Advanced Solid Tumors
Status:
NOT_YET_RECRUITING
Status Verified Date:
2024-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This phase I trial studies the side effects and best dose of vaccine therapy in treating patients with metastatic solid tumors Vaccines made from antibodies and peptides combined with tumor cells may help the body build an effective immune response to kill tumor cells
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None